More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...

CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...

Anktiva plus BCG aims to treat BCG-unresponsive NMIBC with papillary disease, potentially reducing radical cystectomy need. The treatment showed high rates of surgery avoidance and disease-free ...

More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat ...

What Is Imfinzi, and Why Does It Matter? Imfinzi (durvalumab) is a prescription immunotherapy medicine used to treat different types of cancer. The FDA has approved the combination of Imfinzi and ...

NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...

A research team is shedding new light on Bacillus Calmette-Guerin (BCG), a decades-old bladder cancer treatment, which is also given as vaccine against tuberculosis. The findings could help improve ...

Please provide your email address to receive an email when new articles are posted on . Patients with high-risk non-muscle-invasive bladder cancer who received durvalumab plus BCG had improved DFS.

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

Combat Medical (Combat), a medical device company optimizing the delivery and efficacy of cancer therapeutics, today announced it has raised £2.6 million in the first close of a Series A financing to ...

A new study may pave the way toward more personalized treatments for patients with high-risk bladder cancer, according to a study published in European Urology. High-risk non–muscle-invasive bladder ...